BR112014032764A2 - composição farmacêutica contendo fimasartana e hidroclorotiazida - Google Patents

composição farmacêutica contendo fimasartana e hidroclorotiazida

Info

Publication number
BR112014032764A2
BR112014032764A2 BR112014032764A BR112014032764A BR112014032764A2 BR 112014032764 A2 BR112014032764 A2 BR 112014032764A2 BR 112014032764 A BR112014032764 A BR 112014032764A BR 112014032764 A BR112014032764 A BR 112014032764A BR 112014032764 A2 BR112014032764 A2 BR 112014032764A2
Authority
BR
Brazil
Prior art keywords
hydrochlorothiazide
pharmaceutical composition
composition containing
fimasartan
containing fimasartan
Prior art date
Application number
BR112014032764A
Other languages
English (en)
Other versions
BR112014032764B1 (pt
Inventor
Hak Kim Je
Won Kim Ju
Wan Nam Kyung
Yeop Kim Sang
Hun Park Seo
Original Assignee
Boryung Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49783403&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014032764(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boryung Pharm filed Critical Boryung Pharm
Publication of BR112014032764A2 publication Critical patent/BR112014032764A2/pt
Publication of BR112014032764B1 publication Critical patent/BR112014032764B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

resumo composição farmacêutica contendo fimasartana e hidroclorotiazida a presente invenção oferece: uma composição farmacêutica apresentando uma propriedade física superior, uma vez que a fimasartana e a hidroclorotiazida, que são os componentes principais de uma preparação combinada, apresentam uniformidade de conteúdo superior; e um método de sua preparação.
BR112014032764-5A 2012-06-28 2013-04-30 Composição farmacêutica contendo fimasartana e hidroclorotiazida, método para preparação de uma composição farmacêutica e uso de fimasartana e hidroclorotiazida BR112014032764B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20120070359A KR101414873B1 (ko) 2012-06-28 2012-06-28 피마살탄 및 히드로클로로티아지드가 함유된 약제학적 조성물
KR10-2012-0070359 2012-06-28
PCT/KR2013/003734 WO2014003305A1 (ko) 2012-06-28 2013-04-30 피마살탄 및 히드로클로로티아지드가 함유된 약제학적 조성물

Publications (2)

Publication Number Publication Date
BR112014032764A2 true BR112014032764A2 (pt) 2017-06-27
BR112014032764B1 BR112014032764B1 (pt) 2021-12-07

Family

ID=49783403

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014032764-5A BR112014032764B1 (pt) 2012-06-28 2013-04-30 Composição farmacêutica contendo fimasartana e hidroclorotiazida, método para preparação de uma composição farmacêutica e uso de fimasartana e hidroclorotiazida

Country Status (21)

Country Link
US (1) US9457094B2 (pt)
EP (1) EP2868316B1 (pt)
JP (1) JP6145506B2 (pt)
KR (1) KR101414873B1 (pt)
CN (2) CN110496122A (pt)
AU (1) AU2013281582B2 (pt)
BR (1) BR112014032764B1 (pt)
CA (1) CA2877444C (pt)
CL (1) CL2014003525A1 (pt)
CO (1) CO7240413A2 (pt)
ES (1) ES2654207T3 (pt)
IN (1) IN2015DN00645A (pt)
MX (1) MX351521B (pt)
MY (1) MY165075A (pt)
PE (1) PE20150607A1 (pt)
PH (1) PH12014502876B1 (pt)
RU (1) RU2613900C2 (pt)
SG (1) SG11201408666SA (pt)
UA (1) UA111434C2 (pt)
WO (1) WO2014003305A1 (pt)
ZA (1) ZA201409508B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105395552A (zh) * 2014-09-05 2016-03-16 南京华威医药科技开发有限公司 一种含非马沙坦及其盐的固体制剂
KR101545268B1 (ko) * 2015-02-05 2015-08-20 보령제약 주식회사 정제 및 이의 제조방법
WO2017091041A1 (ko) * 2015-11-26 2017-06-01 보령제약 주식회사 피마살탄의 신규 염
SG11201806292QA (en) * 2016-01-27 2018-08-30 Boryung Pharmaceutical Co Ltd Pharmaceutical composition for preventing or treating diabetic nephropathy
KR102233673B1 (ko) * 2016-01-27 2021-03-30 보령제약 주식회사 당뇨병성 신장질환의 예방 또는 치료용 약학적 조성물
CN105784867B (zh) * 2016-03-28 2019-01-01 北京睿创康泰医药研究院有限公司 用于分析非马沙坦有关物质的hplc方法及这些杂质作参比标准的用途
KR102201396B1 (ko) * 2017-11-30 2021-01-11 보령제약 주식회사 피마살탄을 포함하는 약학적 조성물
KR20220162456A (ko) * 2021-06-01 2022-12-08 주식회사 보령 고혈압을 동반한 당뇨병성 신장질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4107831B2 (ja) * 2000-11-21 2008-06-25 第一三共株式会社 医薬組成物
ES2400138T3 (es) 2002-01-16 2013-04-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Comprimido farmacéutico de dos capas que comprende telmisartán y un diurético
KR100678421B1 (ko) * 2005-02-11 2007-02-02 주식회사 씨티씨바이오 염산 탐스로신 함유 방출조절 제제
ATE499090T1 (de) * 2006-06-16 2011-03-15 Lek Pharmaceuticals Pharmazeutische zusammensetzung mit hydrochlorothiazid und telmisartan
EP2203158A4 (en) * 2007-10-30 2012-12-26 Reddys Lab Ltd Dr PHARMACEUTICAL FORMULATIONS WITH TELMISARTAN AND HYDROCHLORTHIAZIDE
ES2364011B1 (es) * 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
KR101058284B1 (ko) 2010-01-22 2011-08-22 보령제약 주식회사 2-(2-ｎ-부틸-4-히드록시-6-메틸-피리미딘-5-일)-Ｎ,Ｎ-디메틸아세트아미드의 신규한 제조방법
TR201004754A1 (tr) * 2010-06-11 2012-01-23 Sanovel �La� San. Ve T�C. A.�. Yeni Farmasötik Kombinasyonlar
CN102397278A (zh) 2010-09-19 2012-04-04 鲁南制药集团股份有限公司 一种抗高血压药物组合物
CN102485228B (zh) 2010-12-02 2015-06-10 鲁南制药集团股份有限公司 一种药物组合物及其用途
CN102485227B (zh) 2010-12-02 2015-06-10 鲁南制药集团股份有限公司 一种药物组合物及其用途
CN102058602B (zh) * 2010-12-21 2013-04-10 中国药科大学 一种稳定的含氯沙坦钾和氢氯噻嗪的口服固体制剂

Also Published As

Publication number Publication date
CN104602676A (zh) 2015-05-06
AU2013281582B2 (en) 2016-06-09
RU2015102553A (ru) 2016-08-20
EP2868316A1 (en) 2015-05-06
SG11201408666SA (en) 2015-03-30
US20150147394A1 (en) 2015-05-28
IN2015DN00645A (pt) 2015-06-26
AU2013281582A1 (en) 2015-02-05
PE20150607A1 (es) 2015-05-16
CA2877444A1 (en) 2014-01-03
JP2015525745A (ja) 2015-09-07
KR20140006233A (ko) 2014-01-16
CN110496122A (zh) 2019-11-26
MX2014015841A (es) 2015-07-17
KR101414873B1 (ko) 2014-07-03
PH12014502876A1 (en) 2015-02-23
EP2868316B1 (en) 2017-12-06
RU2613900C2 (ru) 2017-03-21
CL2014003525A1 (es) 2015-04-10
JP6145506B2 (ja) 2017-06-14
US9457094B2 (en) 2016-10-04
UA111434C2 (uk) 2016-04-25
PH12014502876B1 (en) 2015-02-23
CA2877444C (en) 2017-08-01
ES2654207T3 (es) 2018-02-12
ZA201409508B (en) 2016-08-31
MX351521B (es) 2017-10-18
CO7240413A2 (es) 2015-04-17
WO2014003305A1 (ko) 2014-01-03
MY165075A (en) 2018-02-28
EP2868316A4 (en) 2016-02-17
BR112014032764B1 (pt) 2021-12-07

Similar Documents

Publication Publication Date Title
BR112014032764A2 (pt) composição farmacêutica contendo fimasartana e hidroclorotiazida
CY1122796T1 (el) Βελτιωμενες φαρμακοτεχνικες μορφες αδενοϊων
BR112018010720A8 (pt) agonistas do receptor de apelina e métodos de uso
CL2016002772A1 (es) Composiciones de insulina de rápida acción
EA201890052A1 (ru) Регуляторы nrf2
BR112018010211A2 (pt) formulação farmacêutica aquosa compreendendo anticorpo anti-pd-l1 avelumab
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
CL2014001930A1 (es) Formulacion farmacéutica que comprende un anticuerpo angiopoyetina 2 (anti-ang2).
BR112014017021A8 (pt) inibidores de irak e usos dos mesmos
BR112017007123A2 (pt) derivados de tetrahidroisoquinolina
EA201300146A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ МОДУЛЯТОРА c-МЕТ
EA201591748A1 (ru) Модуляторы p2x7
BR112016018062A8 (pt) compostos terapêuticos, composição farmacêutica e usos
EA202090683A2 (ru) Способы и композиции для лечения рака
EA202191513A1 (ru) Снижение вязкости фармацевтических составов
EA201591196A1 (ru) Композиции и способы для трансдермальной доставки гормонов и других лекарственных средств
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
EA201600124A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
EA201790650A1 (ru) Лекарственная форма и способы применения абиратерона ацетата
BR112016014880A2 (pt) Composição farmacêutica incluindo palonosetron
EA201790570A1 (ru) Модуляторы р2х7
BR112017006552A2 (pt) composições e métodos para inibir a atividade biológica de biomoléculas solúveis
DK3821905T3 (da) Insulin indeholdende farmaceutiske sammensætninger
GEP20186911B (en) Substituted chroman compounds as calcium sensing receptor modulators
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B25G Requested change of headquarter approved

Owner name: BORYUNG PHARMACEUTICAL CO., LTD. (KR)

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/04/2013, OBSERVADAS AS CONDICOES LEGAIS.